Prostaglandin J2  (Synonyms: PGJ2)

Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD)^[1][2][3][4].

Prostaglandin J2 (PGJ2; 33.4 μg/injection; unilateral injection to the SNpc; once per week for 2 or 4 weeks) induces progressive PD-like pathology and exhibites microglia and astrocyte activation and motor deficits in the rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

334.45

C₂₀H₃₀O₄

60203-57-8

Liquid

Colorless to light yellow

CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C=CC1=O)C/C=C\CCCC(O)=O

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. D H Wright, et al. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.  [Content Brief]

  [2]. Nicole Sawyer, et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72.  [Content Brief]

  [3]. Maria E Figueiredo-Pereira, et al. Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration. Ann N Y Acad Sci. 2016 Jan;1363(1):125-37.  [Content Brief]

  [4]. Chuhyon Corwin, et al. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. J Neuroinflammation. 2018 Sep 20;15(1):272.  [Content Brief]